Ignite Creation Date:
2024-05-05 @ 12:01 PM
Last Modification Date:
2024-10-26 @ 9:19 AM
Study NCT ID:
NCT00218049
Status:
TERMINATED
Last Update Posted:
2017-01-12
First Post:
2005-09-16
Brief Title:
Interaction Between Vanoxerine GBR 12909 and Cocaine in Cocaine Dependent Individuals
Sponsor:
National Institute on Drug Abuse NIDA
Organization:
National Institute on Drug Abuse NIDA
Study Overview
Official Title:
Phase 1 Double-blind Placebo-controlled Assessment of Interactions Between 2 Doses of Cocaine and Three Doses of Escalating Vanoxerine GBR 12909 in Cocaine Using Volunteers
Status:
TERMINATED
Status Verified Date:
2008-08
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Issue of priority of resources
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
Cocaine dependence is a major public health problem an effective primary treatment for cocaine dependent individuals has yet to be found The purpose of this study is to determine the safety and effects of vanoxerine GBR 12909 in treating cocaine dependent individuals
Detailed Description:
Cocaine is a strong central nervous system stimulant that is widely abused throughout the United Sates Due to its widespread use it is important to develop an effective treatment for cocaine dependence Dopamine transporters DAT play an important role in the addictive nature of cocaine the use of compounds that target DAT may be effective in treating cocaine dependent individuals Research shows that GBR 12909 has a strong affinity for DAT The purpose of this study is to determine the safety and potential interaction of GBR 12909 and cocaine in cocaine dependent individuals
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| DPMC | None | None | None |
| P50-09262-10 | None | None | None |